Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Owkin

News headline image
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
From Owkin
Via Business Wire
News headline image
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca
From Owkin
Via Business Wire
News headline image
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing
From Owkin
Via Business Wire
News headline image
Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences
From Owkin
Via Business Wire
News headline image
Owkin Brings Biology Super Intelligence Closer to Reality with New AI Infrastructure for Biological Breakthroughs
From Owkin
Via Business Wire
News headline image
Owkin Advances Frontier Model Development for Biological Artificial Super Intelligence, Accelerated by NVIDIA
From Owkin
Via Business Wire
News headline image
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides
From Owkin
Via Business Wire
News headline image
Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI
From Owkin
Via Business Wire
News headline image
Owkin Unveils Europe’s First Pan-European Agentic Infrastructure for Biology at the Franco-German Digital Sovereignty Summit
From Owkin
Via Business Wire
News headline image
Owkin Announces Availability of K Pro in the AWS Marketplace SaaS Category
From Owkin
Via Business Wire
News headline image
Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x
From Owkin
Via Business Wire
News headline image
Owkin Launches ATLANTIS: An Extensive Multimodal Patient Data Discovery Program Across 7 Countries in 11 Therapeutic Areas
From Owkin
Via Business Wire
News headline image
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
From Owkin
Via Business Wire
News headline image
Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare
From Owkin
Via Business Wire
News headline image
Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients
From Owkin
Via Business Wire
News headline image
Owkin Announces MSIntuit® CRC v2, a Next-Generation AI Diagnostic Aimed at Transforming the Detection and Treatment of Colorectal Cancer
From Owkin
Via Business Wire
News headline image
Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer
From Owkin
Via Business Wire
News headline image
Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research
From Owkin
Via Business Wire
News headline image
Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395
From Owkin
Via Business Wire
News headline image
CORRECTING and REPLACING Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin
From Owkin
Via Business Wire
News headline image
Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer
From Owkin
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.